Phase 3, randomized, double-blind, parallel-group, event-based cardiovascular safety study of BI 456906 administered subcutaneously compared with placebo in overweight or obese participants with cardiovascular disease
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: BOEHRINGER INGELHEIM ESPAÑA, SA
- Phase: III
- Execution start: 07/12/2023
- End of execution: 30/09/2026
- PI: MANUEL EDUARDO MUÑOZ TORRES
